English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  Six kinds of oral antidiabetic drugs ( OAD s), including the new dipeptidyl peptidase 4 ( DPP ‐4) inhibitors, are available. The present study aimed to define trends within the prescribing patterns of  OAD s, as well as changes in glycemic control in Japan over a 10‐year period from 2002 to 2011.    Materials and Methods  We carried out a cross‐sectional study using data of type 2 diabetes mellitus patients from 24 clinics for 2002, 2005, 2008 and 2011.  OAD  use was analyzed combined with clinical data.    Results  Sulfonylureas ( SU s) were the most commonly used  OAD , but their use for monotherapy markedly decreased over the study period. Biguanides ( BG s) were the second most commonly used  OAD , and their prescribing rate increased both for mono‐ and combination therapy.  DPP ‐4 inhibitors ( DPP ‐4I), released in 2009, were the third most commonly prescribed  OAD  in 2011 both for mono‐ and combination therapy. Among combination therapies, two  OAD s were mostly prescribed, but the use of three  OAD s and four  OAD s in 2011 was two‐ and 14.8‐fold those in 2002. These trends were accompanied by an improvement in average glycated hemoglobin from 7.5 ± 1.2% in 2002 to 7.1 ± 0.9% in 2011.    Conclusions  The  OAD  prescribing trend has moved away from monotherapy with  SU s and toward combination therapies to achieve better glycemic control. Increased use of  BG s and  DPP ‐4I was predominant in 2011. These trends were accompanied by an improvement of the glycated hemoglobin level.

Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in J apan ( JDDM 32)